Trial · NCT04647110
Outcomes27
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Duration of Treatment: Based on Treatment Cohort Groups | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure based on generation of ALK treatment. | Years | MEAN |
| SECONDARY | Duration of Treatment: Based on Chemotherapy Status | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. | Years | MEAN |
| SECONDARY | Duration of Treatment: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed (N) signifies participants evaluable for this measure and received only 1 line of ALK TKIs with/ without chemotherapy. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had \<5 participants at the index date. | Years | MEAN |
| SECONDARY | Duration of Treatment: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Overall Number of Participants Analyzed (N): participants evaluable for this measure and received only 2 lines of ALK TKIs with/ without chemotherapy. Groups with N =0: no participants with respective ALK TKI sequencing. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had \<5 participants at the index date. | Years | MEAN |
| SECONDARY | Duration of Treatment: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Overall Number of Participants Analyzed (N): participants evaluable for this measure and received only 3 lines of ALK TKIs with/ without chemotherapy. Groups with N =0: no participants with respective ALK TKI sequencing. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had \<5 participants at the index date. | Years | MEAN |
| SECONDARY | Duration of Treatment: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | From index date to treatment completion/discontinuation during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and received \>= 4 lines of ALK TKI treatment with or without chemotherapy. | Years | MEAN |
| PRIMARY | Overall Survival (OS): Based on Treatment Cohort Groups | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure based on generation of ALK treatment. | Years | MEDIAN |
| PRIMARY | Overall Survival: Based on Chemotherapy Status | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. | Years | MEDIAN |
| PRIMARY | Overall Survival: Based on Central Nervous System (CNS) Metastases Status | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. | Years | MEDIAN |
| PRIMARY | Overall Survival: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed (N) signifies participants evaluable for this measure and received only 1 line of ALK TKIs with/ without chemotherapy. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had \<5 participants at the index date. | Years | MEDIAN |
| PRIMARY | Overall Survival: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Overall Number of Participants Analyzed (N): participants evaluable for this measure and received only 2 lines of ALK TKIs with/ without chemotherapy. Groups with N =0: no participants with respective ALK TKI sequencing. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had \<5 participants at the index date. | Years | MEDIAN |
| PRIMARY | Overall Survival: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Overall Number of Participants Analyzed (N): participants evaluable for this measure and received only 3 lines of ALK TKIs with/ without chemotherapy. Groups with N =0: no participants with respective ALK TKI sequencing. Due to ethical compliance, it was pre-planned not to report data for those reporting groups which had \<5 participants at the index date. | Years | MEDIAN |
| PRIMARY | Overall Survival: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | From index date to the date of death due to any cause or censoring date, during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and received \>= 4 lines of ALK TKI treatment with or without chemotherapy. | Years | MEDIAN |
| PRIMARY | Percentage of Participants Alive After 5 Years From Index Date: Based on Treatment Cohort Groups | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed (N) signifies participants who evaluable for this measure with a follow up of 5 years post index date. Reporting groups with N =0 signifies that no participant had a follow up of 5 years post index date. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Alive After 5 Years From Index Date: Based on Chemotherapy Status | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure with a follow up of 5 years post index date. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Alive After 5 Years From Index Date: Based on CNS Metastases Status | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure with a follow up of 5 years post index date. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 1 Line of ALK TKI Treatment | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure with a follow up of 5 years post index date. Reporting arm with Overall Number of Participants Analyzed = 0, signifies that no participant had a follow up of 5 years post index date. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 2 Lines of ALK TKI Treatment | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed (N) signifies participants who evaluable for this measure with a follow up of 5 years post index date. Reporting groups with N =0 signifies that no participant had a follow up of 5 years post index date. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, 3 Lines of ALK TKI Treatment | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed (N) signifies participants who evaluable for this measure with a follow up of 5 years post index date. Reporting groups with N =0 signifies that no participant had a follow up of 5 years post index date. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Alive After 5 Years From Index Date: Based on ALK Sequencing, More Than or Equal to (>=) 4 Lines of ALK TKI Treatment | 5 years post index date during data identification period of 9 years (retrieved data assessed in this observational study for approximately 3 months) | Analysis population included all eligible participants whose data were retrieved from Swedish administrative registers and assessed. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure with a follow up of 5 years post index date. | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04647110/outcomes